Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus

Therapeutic Drug Monitoring

Volumn 29, Issue 1, 2007, Pages 87-95

  Patel, Chirag G ^a   Harmon, Matthew ^a   Gohh, Reginald Y ^b   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Acyl MPAG; Cyclosporine; Ketoconazole; MPAG; Mycophenolic acid; Pharmacokinetics; Tacrolimus

Indexed keywords

ATORVASTATIN; CYCLOSPORIN; GLUCURONIDE; KETOCONAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID ACYL GLUCURONIDE; MYCOPHENOLIC ACID PHENYL GLUCURONIDE; PRAVASTATIN; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY GRAFT; LEUKOPENIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ADMINISTRATION, ORAL; AGED; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CYCLOSPORINE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

EID: 33847137376     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3180318c35     Document Type: Article

References (26)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-2729.
2. Bullingham R, Monroe S, Nicholls A, et al. pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324.
3. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic Acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
4. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol. 2001;132:1027-1034.
5. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
6. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
7. van GT, Meur YL, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28:145-154.
8. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol. 1997;5:225-232.
9. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999;21:35-43.
10. Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006;29:275-280.
11. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by Mrp2 in rats. J Pharmacol Exp Ther. 2004;309:1029-1035.
12. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
13. Gregoor PJ, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
14. Morissette P, Albert C, Busque S, et al. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit. 2001;23:520-525.
15. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
16. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280.
17. Akhlaghi F, Patel CG, Zuniga XP, et al. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit. 2006;28:95-101.
18. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation. 1991;51:365-370.
19. Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit. 2006;28:116-122.
20. Patel CG, Mendonza AE, Akhlaghi F, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:287-294.
21. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333:628-633.
22. Picard N, Cresteil T, Premaud A, et al. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004;26:600-608.
23. Miles KK, Stern ST, Smith PC, et al. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos. 2005;33:1513-1520.
24. Kageyama M, Namiki H, Fukushima H, et al. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull. 2005;28:316-322.
25. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics. 2004;4:2728-2738.
26. Kaplan B, Meier-Kriesche HU, Minnick P, et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of coadministered enteric-coated mycophenolate sodium. Clin Transplant. 2005;19:551-558.